Previous close | 5.80 |
Open | N/A |
Bid | 0.00 |
Ask | 0.00 |
Strike | 64.00 |
Expiry date | 2024-06-14 |
Day's range | 5.80 - 5.80 |
Contract range | N/A |
Volume | |
Open interest | 2 |
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in June: Jefferies Global Healthcare Conference: Robert I. Blum, President and Chief Executive Officer, and Andrew Callos, Executive Vice President and Chief Commercial Officer, will participate in a fireside chat on Wednesday, June 5, 2024 at 2:00 PM Eastern Time at the New York Marriott Marquis
SOUTH SAN FRANCISCO, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing of its previously announced underwritten public offering of 9,803,922 shares of its common stock at a price to the public of $51.00 per share. The gross proceeds to Cytokinetics from the offering, before offering expenses payable by Cytokinetics, were approximately $500 million. J.P. Morgan, Goldman Sachs & Co. LLC and Morgan Stanley acted as joint book-running mana
We recently compiled a list of the 7 Best Mid-Cap Healthcare Stocks To Buy Now and in this article we discuss whether Cytokinetics, Incorporated (NASDAQ:CYTK) is the best mid-cap healthcare stock to buy now according to hedge funds. Challenges in the Health Sector The healthcare industry is considered to be a fairly defensive sector due […]